RxDoctor Payments DataLook up a doctor →

John Gabriel, MD

Family Medicine · North Richland Hills, TXNPI 1407844764

Payments from drug & device makers

$7,776,125in general payments, 2019–2025

Across 1,025 payments — averaging $7586.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$6.3M
  • Novartis$1.1M
  • Chiesi USA, Inc.$185K
  • Sanofi US Services Inc.$85K
  • AbbVie$46K
  • AstraZeneca$20K
  • plus $27K from 54 others
$47,076in research payments, 2019–2025

Across 12 payments — averaging $3922.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$47K

What the payments were for

  • Consulting fees$5,06319%
  • Travel & lodging$7,52228%
  • Food & beverage$13,78752%
  • Education$1090%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly79$6,311,797
Novartis29$1,100,972
Chiesi USA, Inc.25$185,484
Sanofi US Services Inc.16$85,003
AbbVie(2 entities)126$45,574
AstraZeneca53$19,811
Ardelyx, Inc.1$11,000
Novo Nordisk87$4,839
Biohaven Pharmaceutical Holding Company Ltd.10$1,757
Merck36$1,518
GSK62$1,067
Lilly USA, LLC76$938
Boehringer Ingelheim53$623
Pfizer48$541
Abbott25$477
Takeda Pharmaceuticals U.S.A., Inc.32$369
Amgen29$360
Corium, LLC11$317
Astellas Pharma US Inc15$316
Amarin Pharma, Inc.19$314
Antares Pharma, Inc.14$237
Sanofi-aventis U.S. LLC15$235
Exact Sciences13$230
Tris Pharma Inc12$211
Daiichi Sankyo Inc.10$174
Idorsia Pharmaceuticals US Inc10$166
Supernus Pharmaceuticals, Inc.9$153
Johnson & Johnson(2 entities)11$149
Eisai Inc.8$127
Althera Pharmaceuticals LLC8$98
Dexcom, Inc.6$97
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC6$91
Biohaven Pharmaceuticals, Inc.5$83
Genentech USA, Inc.5$76
Teva Pharmaceuticals USA, Inc.5$62
Otsuka America Pharmaceutical, Inc.3$57
Noven Therapeutics, LLC4$54
Bayer4$54
Verity Pharmaceuticals Inc.3$51
Phathom Pharmaceuticals, Inc.3$47
Ironwood Pharmaceuticals, Inc3$42
Jazz Pharmaceuticals Inc.2$38
Tolmar, Inc.2$32
Neos Therapeutics, LP2$30
Aytu Biopharma, Inc.2$28
Scynexis, Inc.2$27
Boston Scientific1$27
Philips North America LLC1$23
Arbor Pharmaceuticals, Inc.2$23
Corcept Therapeutics1$22
Upsher-smith Laboratories LLC1$19
Scilex Pharmaceuticals Inc.1$19
Nevro Corp.1$18
Halozyme Inc1$17
Axsome Therapeutics, Inc.1$16
Mission Pharmacal Company1$16
Sunovion Pharmaceuticals Inc.1$16
Impel Pharmaceuticals Inc.1$16
Lucid Diagnostics Inc.1$15
E.r. Squibb & Sons, L.L.C.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,776,125 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$188,257
Medicare patients
466
Services billed
10,933

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide74$73,598
JardianceEmpagliflozin49$46,510
MounjaroTirzepatide24$23,172
TrulicityDulaglutide11$15,354
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$13,748
SymbicortBudesonide/Formoterol Fumarate27$7,826
Lantus SolostarInsulin Glargine,hum.Rec.Anlog15$4,182
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen158$3,494
Omeprazole147$3,071
Sucralfate37$2,627
Levothyroxine Sodium231$2,189
Levemir FlexpenInsulin Detemir16$2,078
Gabapentin101$1,788
Diclofenac Sodium119$1,785
Atorvastatin Calcium274$1,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$4,839$73,59874 claims
Boehringer IngelheimJardiance$623$46,51049 claims
Lilly USA, LLCMounjaro, Trulicity$938$38,52535 claims
GSKTrelegy Ellipta$1,067$13,74820 claims
AstraZenecaSymbicort$19,811$7,82627 claims
AbbVieSynthroid$45,574$82313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in North Richland Hills

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →